Evaluation of Efficacy and Safety of Qiangzhu-qinggan Formula As an Adjunctive Therapy in Adult Patients with Severe Influenza: Study Protocol for a Randomized Parallel Placebo-controlled Double-blind Multicenter Trial

Overview

Journal Trials

Publisher Biomed Central

Specialties General Medicine
Pharmacology

Date 2021 Dec 28

PMID 34961550

Authors

Lei Qiu

Xian-Wei Wu

Shao-Yan Zhang

Ming Yang

Shun-Xian Zhang

Ji-You Fu

Cui Li

Zhi-Jie Zhang

Pei-Yong Zheng

Zhen-Hui Lu

Affiliations

Soon will be listed here.

Abstract

Background: Influenza can fall into three categories according to severity: mild influenza, severe influenza, and critical influenza. Severe influenza can result in critical illness and sometimes death particularly in patients with comorbidities, advanced age, or pregnancy. Neuraminidase inhibitors (NAIs) are the only antiviral drugs in widespread use for influenza. However, the effectiveness of NAIs against severe influenza is uncertain. New effective drugs or regimens are therefore urgently needed. Qiangzhu-qinggan (QZQG) formula has been found to be effective against influenza virus infection during long-term application in China, which lacks support of evidence-based clinical trial till now. This study is designed to assess the efficacy and safety of QZQG formula as an adjuvant therapy in adult patients with severe influenza.

Methods: This protocol is drawn up in accordance with the SPIRIT guidelines and CONSORT Extension for Chinese herbal medicine formulas. This is a randomized, placebo-controlled, double-blind, multicenter trial. Two hundred twenty-eight adults with severe influenza are randomly assigned in a 1:1 ratio to QZQG or placebo for 7 days. All participants need to receive 1 day of screening before randomization, 7 days of intervention, and 21 days of observation after randomization. The primary outcome is the proportion of clinical improvement, defined as the proportion of patients who met the criteria of 3 points or less in the seven-category ordinal scale or 2 points or less in National Early Warning Score 2 within 7 days after randomization.

Discussion: This is the first randomized, controlled, parallel, double-blind clinical trial to evaluate the efficacy and safety of traditional Chinese herbal formula granules as an adjuvant therapy in adult patients with severe influenza. This study aims to redefine the value of traditional Chinese herbal medicines in the treatment of virus-related respiratory infectious diseases and serves as an example of evidence-based clinical trials of other Chinese herbal medicines.

References

Zhong Y, Fu J, Liu X, Diao X, Mao B, Fan T . The reporting quality, scientific rigor, and ethics of randomized placebo-controlled trials of traditional Chinese medicine compound formulations and the differences between Chinese and non-Chinese trials. Curr Ther Res Clin Exp. 2014; 71(1):30-49. PMC: 3967323. DOI: 10.1016/j.curtheres.2010.02.001. View

Liu Q, Lu L, Hua M, Xu Y, Xiong H, Hou W . Jiawei-Yupingfeng-Tang, a Chinese herbal formula, inhibits respiratory viral infections in vitro and in vivo. J Ethnopharmacol. 2013; 150(2):521-8. DOI: 10.1016/j.jep.2013.08.056. View

Beumer M, Koch R, van Beuningen D, OudeLashof A, van de Veerdonk F, Kolwijck E . Influenza virus and factors that are associated with ICU admission, pulmonary co-infections and ICU mortality. J Crit Care. 2018; 50:59-65. PMC: 7125534. DOI: 10.1016/j.jcrc.2018.11.013. View

Iuliano A, Roguski K, Chang H, Muscatello D, Palekar R, Tempia S . Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2017; 391(10127):1285-1300. PMC: 5935243. DOI: 10.1016/S0140-6736(17)33293-2. View

Peterson R, Vock D, Powers J, Emery S, Cruz E, Hunsberger S . Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization. Clin Trials. 2017; 14(3):264-276. PMC: 5528156. DOI: 10.1177/1740774517697919. View

Lee J, Edward C Abundo M, Lee C . Herbal Medicines with Antiviral Activity Against the Influenza Virus, a Systematic Review. Am J Chin Med. 2019; 46(8):1663-1700. DOI: 10.1142/S0192415X18500854. View

Wang C, Cao B, Liu Q, Zou Z, Liang Z, Gu L . Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med. 2011; 155(4):217-25. DOI: 10.7326/0003-4819-155-4-201108160-00005. View

Uyeki T, Bernstein H, Bradley J, Englund J, File T, Fry A . Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis. 2018; 68(6):e1-e47. PMC: 6653685. DOI: 10.1093/cid/ciy866. View

Beigel J, Tebas P, Elie-Turenne M, Bajwa E, Bell T, Cairns C . Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respir Med. 2017; 5(6):500-511. PMC: 5828518. DOI: 10.1016/S2213-2600(17)30174-1. View

10.

Gao G . From "A"IV to "Z"IKV: Attacks from Emerging and Re-emerging Pathogens. Cell. 2018; 172(6):1157-1159. PMC: 7126677. DOI: 10.1016/j.cell.2018.02.025. View

11.

Duan Z, Jia Z, Zhang J, Liu S, Chen Y, Liang L . Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial. Chin Med J (Engl). 2011; 124(18):2925-33. View

12.

Ding Y, Zeng L, Li R, Chen Q, Zhou B, Chen Q . The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC Complement Altern Med. 2017; 17(1):130. PMC: 5324200. DOI: 10.1186/s12906-017-1585-7. View

13.

Heo Y . Baloxavir: First Global Approval. Drugs. 2018; 78(6):693-697. DOI: 10.1007/s40265-018-0899-1. View

14.

Li Z, Li L, Chen T, Li C, Wang D, Yang Z . Efficacy and safety of Ban-Lan-Gen granules in the treatment of seasonal influenza: study protocol for a randomized controlled trial. Trials. 2015; 16:126. PMC: 4383212. DOI: 10.1186/s13063-015-0645-x. View

15.

Wang Y, Fan G, Salam A, Horby P, Hayden F, Chen C . Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection. J Infect Dis. 2019; 221(10):1688-1698. DOI: 10.1093/infdis/jiz656. View

16.

Li L, Liu Y, Wu P, Peng Z, Wang X, Chen T . Influenza-associated excess respiratory mortality in China, 2010-15: a population-based study. Lancet Public Health. 2019; 4(9):e473-e481. PMC: 8736690. DOI: 10.1016/S2468-2667(19)30163-X. View

17.

Wang Y, Fan G, Horby P, Hayden F, Li Q, Wu Q . Comparative Outcomes of Adults Hospitalized With Seasonal Influenza A or B Virus Infection: Application of the 7-Category Ordinal Scale. Open Forum Infect Dis. 2019; 6(3):ofz053. PMC: 6419989. DOI: 10.1093/ofid/ofz053. View

18.

Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y . Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395(10236):1569-1578. PMC: 7190303. DOI: 10.1016/S0140-6736(20)31022-9. View

19.

Poon P, Wong C, Fung K, Fong C, Wong E, Lau J . Immunomodulatory effects of a traditional Chinese medicine with potential antiviral activity: a self-control study. Am J Chin Med. 2006; 34(1):13-21. DOI: 10.1142/S0192415X0600359X. View

20.

Wang Y, Zhou F, Zhang D, Zhao J, Du R, Hu Y . Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial. Trials. 2020; 21(1):422. PMC: 7245636. DOI: 10.1186/s13063-020-04352-9. View